| GlaxoSmithKline AG - Infanrix DTPa-IPV, Injektionssuspension | | 00638 | | 01 | | Infanrix DTPa-IPV | | Injektionssuspension | | J07CA02 | | Diphtherie-Pertussis-Poliomyelitis-Tetanus | | 20.08.1999 | | |
| | Composition | | toxoidum diphtheriae min. 30 U.I., toxoidum tetani min. 40 U.I., toxoidum pertussis 25 µg, haemagglutininum filamentosum (B. pertussis) 25 µg, pertactinum (B. pertussis) 8 µg, virus poliomyelitis typus 1 inactivatus (Stamm Mahoney) 40 U.I., virus poliomyelitis typus 2 inactivatus (Stamm MEF-1) 8 U.I., virus poliomyelitis typus 3 inactivatus (Stamm Saukett) 32 U.I., aluminium 0.5 mg ut aluminii hydroxidum hydricum ad adsorptionem, natrii chloridum corresp. natrium 1.8 mg, medium 199, aqua ad iniectabile ad suspensionem pro 0.5 ml, residui: neomycini sulfas, polymyxini B sulfas, formaldehydum, polysorbatum 80. | | Packungsbestandteile | | Principe actif | Concentr. |
|---|
| | 25 mcg | | | 8 mcg | | | | | | 25 mcg | | | | | | 40 UI | | | 8 UI | | | 32 UI |
| | BAG: Principe actif | Concentr. |
|---|
| | 25 mcg | | | 8 mcg | | | | | | 25 mcg | | | | | | 40 UI | | | 8 UI | | | 32 UI |
|
| | numéro d'emballage | Taille des présentations | PEF | PP | Cat. | LS | Hors commerce (MedRef) |
|---|
| 003 | | 20.20 | 38.40 | B | LS | Non |
|
|
